Today ACUR ranks # as BUY CANDIDATE.
Today ACUR ranks # as BUY CANDIDATE.

ACUR stock Acura Pharmaceuticals

ACUR stock
Acura Pharmaceuticals

18 January 2019
Change 24.81%
Chart period: 2018-10-19 - 2019-01-18




Request Prediction

Acura Pharmaceuticals Stock Analysis

Technical stock analysis for 18 January 2019

Buy candidate since 2019-01-18

Acura Pharmaceuticals gained 24.81% in the last trading day, rising from $0.13 to $0.16 The price has risen in 4 of the last 10 days and is up by 35.91% over the past 2 weeks. Volume fell in the last day by -10 945 shares, and in total, 5 522 shares bought and sold for approximately $902.85. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes for the next couple of days.

Close price at the end of the last trading day (Friday, 18th Jan 2019) of the ACUR stock was $0.16. This is 24.81% more than the trading day before Thursday, 17th Jan 2019.

During day the stock fluctuated 9.00% from a day low at $0.15 to a day high of $0.16.

30 day high of the ACUR stock price was $0.18 and low was $0.06.
90 day high was $0.30 and low was $0.06.
52 week high for the Acura Pharmaceuticals - $0.84 and low - $0.06.


Acura Pharmaceuticals lies the upper part of a very wide and falling trend in the short term, and this will normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $0.17 will firstly indicate a slower falling rate, but may be the first sign of a trend shift. Given the current short-term trend, the stock is expected to fall -45.61% during the next 3 months and, with 90% probability hold a price between $0.02 and $0.09 at the end of this period.

Click here for today's Top 5 Trending Companies


Acura Pharmaceuticals holds buy signals from both short- and long-term moving averages. In addition, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down there will be some support from the lines at $0.16 and $0.15. A break down below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Thursday January 17, 2019, which indicates further gains until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may not be. The very low volume increases the risk and reduces the other technical signals issued.

Access today's Top 5 Golden Star Companies

Relative Strength Index (RSI)

RSI14 is 65 and the stock is currently not being overbought or oversold

Access full RSI 14 and RSI 21 lists

Support & Resistance

On the downside, the stock finds support just below today's level from accumulated volume at $0.15 and $0.14.

There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Acura Pharmaceuticals finds support just below today's level at $0.15. If this is broken, then the next support from accumulated volume will be at $0.14 and $0.13.

Support: $0.15 Price: $0.16 Resistance: $0.16


This stock may move much during a day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.01 between high and low, or 9.00%. For the last week the stock has had a daily average volatility of 16.75%.

Our recommended stoploss: $0.15 (-5.72%) (This stock has very high daily movements and this gives very high risk. There is a buy signal from pivot bottom found 1 days ago.)

Overall risk:

Very Low Low Medium High Very High


Several short-term signals are positive, despite the stock being in a falling trend, we conclude that the current level may hold a buying opportunity as there is a fair chance for this stock to perform well in the short-term. We have upgraded our recommendation for this stock since last evaluation from a Sell Candidate to a Buy Candidate.

Today ACUR ranks # as BUY CANDIDATE.
Today ACUR ranks # as BUY CANDIDATE.